Laura K. Bachrach

Publication Details

  • Inadequate Vitamin D Status in Adolescents with Substantial Bone Mineral Density Loss During the Use of Depot Medroxyprogesterone Acetate Injectable Contraceptive: A Pilot Study JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY Harel, Z., Wolter, K., Gold, M. A., Cromer, B., Bruner, A., Stager, M., Bachrach, L., Hertweck, P., Nelson, A., Nelson, D., Coupey, S., Johnson, C. C., Burkman, R., Bone, H. 2010; 23 (4): 209-214


    To examine vitamin D and parathormone (PTH) levels in adolescents who experienced substantial bone mineral density (BMD) loss during depot medroxyprogesterone acetate (DMPA) use.A non-randomized, multi-center study, during which DMPA was administered every 12 weeks and evaluation of lumbar spine and hip BMD by dual-energy X-ray absorptiometry (DXA) was conducted every 6 months. A blood sample for vitamin D and PTH measurements was obtained from adolescents who experienced >5% BMD loss. Vitamin D deficiency was defined as 25-hydroxyvitamin D (25OHD) level of <20 ng/mL, insufficiency as 25OHD level of 20-30 ng/mL, and sufficiency as 25OHD level of >30 ng/mL.Evaluation of vitamin D and PTH was carried out in 15 participants who experienced BMD loss of > or = 5% during DMPA use. At initiation of DMPA, participants had mean (+SE) age 17+1 years, gynecologic age 61+4 months, and body mass index 24+1.5 kg/m2. Racial/ethnic distribution was: Caucasian--7 girls, Hispanic--4 girls, African-American--3 girls, and other--1 girl. Six participants had BMD loss of >5% after 2 DMPA injections, five after 3 injections, one after 5 injections, one after 8 injections, one after 10 injections, and one after 13 injections. Only one girl (7%) had sufficient vitamin D. The other participants had vitamin D insufficiency (50%) or deficiency (43%). Participants' mean (+SE) PTH was 22+4 pg/mL (reference range 7-53 pg/mL), and mean (+SE) 1,25-dihydroxyvitamin D was 56+5 pg/mL (reference range 22-67 pg/mL).Inadequate vitamin D status was evident among the majority of female adolescents who experienced a substantial BMD loss while using DMPA.

    View details for DOI 10.1016/j.jpag.2009.11.004

    View details for Web of Science ID 000279744200004

    View details for PubMedID 20471875

Stanford Medicine Resources:

Footer Links: